| Reversal of indoleamine 2, 3-dioxygenase–mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme TA Triplett, KC Garrison, N Marshall, M Donkor, J Blazeck, C Lamb, ... Nature biotechnology 36 (8), 758-764, 2018 | 231 | 2018 |
| Defining a functionally distinct subset of human memory CD4+ T cells that are CD25POS and FOXP3NEG TA Triplett, BD Curti, PR Bonafede, WL Miller, EB Walker, AD Weinberg European journal of immunology 42 (7), 1893-1905, 2012 | 72 | 2012 |
| Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression WL Redmond, T Triplett, K Floyd, AD Weinberg PloS one 7 (4), e34467, 2012 | 58 | 2012 |
| Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: results from the IMPACC study A Ozonoff, J Schaenman, ND Jayavelu, CE Milliren, CS Calfee, CB Cairns, ... EBioMedicine 83, 2022 | 31 | 2022 |
| Endogenous dendritic cells from the tumor microenvironment support T-ALL growth via IGF1R activation TA Triplett, KT Cardenas, JN Lancaster, Z Hu, HJ Selden, GJ Jasso, ... Proceedings of the National Academy of Sciences 113 (8), E1016-E1025, 2016 | 29 | 2016 |
| STAT3 signaling is required for optimal regression of large established tumors in mice treated with anti-OX40 and TGFβ receptor blockade TA Triplett, CG Tucker, KC Triplett, Z Alderman, L Sun, LE Ling, ... Cancer immunology research 3 (5), 526-535, 2015 | 29 | 2015 |
| Current methods in translational cancer research MW Lee, M Miljanic, T Triplett, C Ramirez, KL Aung, SG Eckhardt, ... Cancer and Metastasis Reviews 40, 7-30, 2021 | 28 | 2021 |
| Microglia depletion and alcohol: Transcriptome and behavioral profiles AS Warden, TA Triplett, A Lyu, EK Grantham, MM Azzam, A DaCosta, ... Addiction biology 26 (2), e12889, 2021 | 26 | 2021 |
| Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer MJ Bloom, AM Jarrett, TA Triplett, AK Syed, T Davis, TE Yankeelov, ... BMC cancer 20, 1-13, 2020 | 18 | 2020 |
| Tumor-associated myeloid cells provide critical support for T-ALL A Lyu, TA Triplett, SH Nam, Z Hu, D Arasappan, WH Godfrey, RY Ames, ... Blood, The Journal of the American Society of Hematology 136 (16), 1837-1850, 2020 | 18 | 2020 |
| A novel approach to targeting the IDO/TDO pathway through degradation of the immunosuppressive metabolite kynurenine M Zhang, E Stone, TA Triplett, K Triplett, C Lamb, CS Karamitros, J Blazek, ... Cancer Research 77 (13_Supplement), 5570-5570, 2017 | 12 | 2017 |
| Covalent JNK inhibitor, JNK-IN-8, suppresses tumor growth in triple-negative breast cancer by activating TFEB-and TFE3-mediated lysosome biogenesis and autophagy M Soleimani, A Somma, T Kaoud, R Goyal, J Bustamante, DC Wylie, ... Molecular Cancer Therapeutics 21 (10), 1547-1560, 2022 | 10 | 2022 |
| Abstract LB-226: Depletion of kynurenine using an engineered therapeutic enzyme potently inhibits cancer immune checkpoints both as a monotherapy and in combination with anti-PD-1 E Stone, N Marshall, M Donkor, K Triplett, J Blazek, T Triplett, L Ehrlich, ... Cancer Research 75 (15_Supplement), LB-226-LB-226, 2015 | 9 | 2015 |
| Immune checkpoint blockade in gastrointestinal cancers: the current status and emerging paradigms M Miljanic, A Capasso, TA Triplett, SG Eckhardt, KL Aung Journal of Immunotherapy and Precision Oncology 3 (1), 3-15, 2020 | 4 | 2020 |
| Immune-checkpoint inhibition via enzyme-mediated degradation of kynurenine TA Triplett, K Triplett, E Stone, M Zhang, M Manfredi, C Lamb, Y Tanno, ... Cancer Research 77 (13_Supplement), 5571-5571, 2017 | 4 | 2017 |
| Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies KG Anderson, DA Braun, A Buqué, SB Gitto, JL Guerriero, B Horton, ... Journal for immunotherapy of cancer 11 (6), 2023 | 3 | 2023 |
| Phase 1 study of OKI-179, an oral class 1-selective depsipeptide HDAC inhibitor, in patients with advanced solid tumors: Final results. JA Kagihara, B Corr, JM Pacheco, SL Davis, CH Lieu, SS Kim, A Jimeno, ... Journal of Clinical Oncology 39 (15_suppl), 3075-3075, 2021 | 3 | 2021 |
| Elucidating the role of HDACs in T cell biology and comparing distinct HDAC inhibitors in augmenting responses to cancer immunotherapy TA Triplett, N Holay, S Kottapalli, C VanDenBerg, A Capasso The Journal of Immunology 204 (1_Supplement), 165.23-165.23, 2020 | 3 | 2020 |
| Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy N Holay, A Somma, M Duchow, M Soleimani, A Capasso, S Kottapalli, ... Frontiers in Immunology 14, 1260545, 2023 | 1 | 2023 |
| Longitudinal COVID-19 immune trajectories in patients with neurological autoimmunity on anti-CD20 therapy SA Bazzi, C Maguire, N Holay, J Geltman, K Hurley, C DiPasquale, ... Multiple Sclerosis and Related Disorders 68, 104195, 2022 | 1 | 2022 |
